Researchers create an atlas of health associations for GLP-1 receptor agonists

Researchers create an atlas of health associations for GLP-1 receptor agonists

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for gastrointestinal and musculoskeletal issues.

How GLP-1 drugs like Ozempic and Wegovy affect risk of 175 conditions

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

What can’t GLP-1s do? Study maps benefits while warning of uncommon risks

A large survey of VA patients looked at effects beyond obesity and weight loss and found 42 ways GLP-1s may help, 19 ways they may harm.

GLP-1 Agents’ Risks and Benefits Broader Than Previously Thought – News 7

An observational study of 175 health outcomes using Veterans Affairs (VA) data for nearly 2 million individuals uncovered new insights about possible risks and benefits of GLP-1 receptor agonists. Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment plan had significantly decreased risks for 42 diverse outcomes, increased risks for 19 outcomes, and no association with 114 outcomes compared with usual

Mapping the effectiveness and risks of GLP-1 receptor agonists

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes. Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA (n = 215,970) and compared them to those who initiated sulfonylureas (n = 159,

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. ASC30 oral tablet was generally safe and well tolerated. All adverse events (AEs) were mild (grade 1) or moderate (grade […]